In line with our previous observation, immunoreactivity against GLS1 was observed primarily in the cytoplasm of HCC cells, and was strongly positive (++) in about 80% of HCC (72 of 90 cases), weak (+) in 16.67% (15/90), and was absent in 3.33% (3/90) cases. This evidence concerns the gene GLS and hepatocellular carcinoma.